Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Melanoma Peptide Vaccines and Sargramostim in Stage IV Melanoma
NCT00006243Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Oct 2000
- Primary completion
- May 2006
- Modality
- Recombinant Proteins and Enzymes, Peptides, Peptide-based Cancer Vaccines
- Countries
- 1
01
Overview
A Phase 2 trial of MART-1(27-35) peptide vaccine, tyrosinase peptide, gp100:209-217, sargramostim in melanoma, sponsored by National Cancer Institute. Started Oct 2000; status: completed.
02
Drugs
MART-1(27-35) peptide vaccinetyrosinase peptidegp100:209-217sargramostim
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT00006243.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00006243.